Enlivex Therapeutics Shares Set to Reverse Split on Tuesday, October 27th (NASDAQ:ENLV)

Enlivex Therapeutics Ltd. (NASDAQ:ENLV)’s stock is scheduled to reverse split on Tuesday, October 27th. The 1-16 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, October 26th.

Enlivex Therapeutics Price Performance

Enlivex Therapeutics stock traded down $0.03 on Friday, reaching $0.17. The company’s stock had a trading volume of 655,132 shares, compared to its average volume of 2,489,173. The business’s fifty day moving average price is $0.79 and its 200 day moving average price is $6.06. Enlivex Therapeutics has a twelve month low of $0.17 and a twelve month high of $27.15.

Analyst Upgrades and Downgrades

Several research firms have issued reports on ENLV. Weiss Ratings reissued a “sell (d)” rating on shares of Enlivex Therapeutics in a research note on Tuesday, September 22nd. Zacks Research lowered Enlivex Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 2nd. Finally, Wall Street Zen upgraded Enlivex Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 29th. One analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Enlivex Therapeutics presently has an average rating of “Hold” and a consensus price target of $247.50.

Institutional Investors Weigh In On Enlivex Therapeutics

Several institutional investors have recently made changes to their positions in the stock. WINTON GROUP Ltd bought a new stake in Enlivex Therapeutics during the second quarter worth $55,000. Susquehanna International Group LLP boosted its holdings in shares of Enlivex Therapeutics by 1,428.5% in the 2nd quarter. Susquehanna International Group LLP now owns 157,648 shares of the company’s stock valued at $87,000 after purchasing an additional 147,334 shares in the last quarter. Finally, Bank of America Corp DE increased its stake in shares of Enlivex Therapeutics by 53.2% in the 1st quarter. Bank of America Corp DE now owns 130,401 shares of the company’s stock valued at $121,000 after purchasing an additional 45,303 shares during the last quarter. 1.02% of the stock is currently owned by institutional investors.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics Ltd. is a clinical-stage biotechnology company developing immunotherapies designed to restore immune-system balance in conditions associated with excessive or dysregulated inflammation. The company is based in Israel and trades on the Nasdaq under the symbol ENLV.

Enlivex’s lead product candidate is Allocetra, an investigational, off-the-shelf cell therapy intended to reprogram immune cells known as macrophages and promote immune homeostasis. The therapy is being studied as a potential treatment for severe inflammatory conditions, including sepsis and osteoarthritis of the knee.

The company’s clinical development activities have included studies in Israel and other locations, with programs focused on evaluating Allocetra’s safety and potential efficacy.